The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Annals of Oncology

Volumn 22, Issue SUPPL. 5, 2011, Pages

  van Cutsem, E ^a   Dicato, M ^b   Geva, R ^a,c   Arber, N ^c   Bang, Y ^d   Benson, A ^e   Cervantes, A ^f   Diaz Rubio, E ^g   Ducreux, M ^h   Glynne Jones, R ⁱ   Grothey, A ^j   Haller, D ^k   Haustermans, K ^a   Kerr, D ^l   Nordlinger, B ^m   Marshall, J ⁿ   Minsky, B D ^o   Kang, Y K ^p   Labianca, R ^q   Lordick, F ^r   Ohtsu, A ^s   Pavlidis, N ^t   Roth, A ^u   Rougier, P ^v   Schmoll, H J ^w   Sobrero, A ^x   Tabernero, J ^y   van de Velde, C ^z   Zalcberg, J ^aa   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Luxembourg Medical Center   (Luxembourg)

^c TEL AVIV UNIVERSITY   (Israel)

^d Seoul National University College of Medicine   (South Korea)

^e NORTHWESTERN UNIVERSITY   (United States)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ MOUNT VERNON CANCER CENTRE   (United Kingdom)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m HÔPITAL AMBROISE PARÉ   (France)

ⁿ GEORGETOWN UNIVERSITY   (United States)

^o UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^p Asan Medical Center   (South Korea)

^q Ospedali RUINITI   (Italy)

^r Hematology and Oncology Clinic Braunschweig   (Germany)

^s NATIONAL CANCER CENTER HOSPITAL   (Japan)

^t UNIVERSITY OF IOANNINA   (Greece)

^u GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^v HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^w MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^x UNIVERSITY OF GENOA   (Italy)

^y HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^z LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^aa PETER MACCALLUM CANCER CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PLACEBO; TRASTUZUMAB;

ADVANCED CANCER; CALORIC INTAKE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CARDIOVASCULAR RISK; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG FATALITY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL ADENOCARCINOMA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; INTENSITY MODULATED RADIATION THERAPY; LOWER ESOPHAGUS SPHINCTER; META ANALYSIS (TOPIC); METASTASIS POTENTIAL; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER;

EID: 79958106046     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr284     Document Type: Conference Paper

References (109)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002; 5 (suppl 1): 5-11.
3. Devesa SS, Fraumeni JF Jr. The rising incidence of gastric cardia cancer. J Natl Cancer Inst 1999; 91: 747-749.
4. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002; 11: 235-256.
5. Anderson WF, Camargo MC, Fraumeni JF, Jr et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010; 303: 1723-1728.
6. Tredaniel J, Boffetta P, Buiatti E et al. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 1997; 72: 565-573.
7. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007; 10: 75-83.
8. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9.
9. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211.
10. Whiteman DC, Sadeghi S, Pandeya N et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57: 173-180.
11. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
12. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
13. Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179: 1523-1530.
14. Limburg P, Qiao Y, Mark S et al. Helicobacter pylori seropositivity and subsitespecific gastric cancer risks in Linxian, China. J Natl Cancer Inst 2001; 93: 226-233.
15. Akoh JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992; 79: 293-299.
16. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2: 98-107.
17. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333: 32-41.
18. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg 2007; 245: 777-783.
19. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000; 18: 2327-2340.
20. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789.
21. Fuccio L, Zagari RM, Minardi ME, Bazzoli F. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 25: 133-141.
22. Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol 2007; 102: 1789-1798.
23. Ito M, Takata S, Tatsugami M et al. Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol 2009; 44: 365-371.
24. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-397.
25. Hamaguchi K, Ogawa K, Katsube T et al. Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication. Langenbecks Arch Surg 2004; 389: 83-91.
26. Nakane Y, Okamura S, Akehira K et al. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. Cancer 1994; 73: 2703-2708.
27. Cidon EU, Bustamante R. Gastric cancer: tumor markers as predictive factors for preoperative staging. J Gastrointest Cancer 2010: 2010 May 25 [Epub ahead of print].
28. Ucar E, Semerci E, Ustun H et al. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008; 25: 1075-1084.
29. Mattar R, Alves de Andrade CR, DiFavero GM et al. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 2002; 57: 89-92.
30. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol 2007; 25: 2107-2116.
31. Kinkel K, Lu Y, Both M et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224: 748-756.
32. Lim JS, Yun MJ, Kim MJ et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006; 26: 143-156.
33. De Potter T, Flamen P, Van Cutsem E et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29: 525-529.
34. de Graaf GW, Ayantunde AA, Parsons SL et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007; 33: 988-992.
35. Blackshaw GR, Barry JD, Edwards P et al. Laparoscopy significantly improves the perceived preoperative stage of gastric cancer. Gastric Cancer 2003; 6: 225-229.
36. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
37. Li H, Cao Y, Zhai L, Lin T. Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer. J Clin Oncol 2010; 28 (7 suppl): Abstract 4042.
38. Ronellenfitsch U, Schwarzbach M, Hofheinz R et al. Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma). J Clin Oncol 2010; 28 (7 suppl): Abstract 4022.
39. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
40. Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: a FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011 Mar 28 [Epub ahead of print].
41. Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.
42. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
43. Macdonald J, Smalley S, Haller D et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009; 27 (15 suppl): (abstr 4515).
44. Orditura M, De Vita F, Muto P et al. Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg 2010; 145: 233-238.
45. Leong T, Joon DL, Willis D et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after threedimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2011; 79: 690-695.
46. Matzinger O, Gerber E, Bernstein Z et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009; 92: 164-175.
47. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-1459.
48. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographicanatomic subclassification. J Surg Oncol 2005; 90: 139-146.
49. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
50. Power DG, Reynolds JV. Localized adenocarcinoma of the esophagogastric junction-is there a standard of care? Cancer Treat Rev 2010; 36: 400-409.
51. Kang HJ, Kim DH, Jeon TY et al. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. Gastrointest Endosc 2010; 72: 508-515.
52. Li H, Lu P, Lu Y et al. Predictive factors of lymph node metastasis in undifferentiated early gastric cancers and application of endoscopic mucosal resection. Surg Oncol 2010; 19: 221-226.
53. Park JC, Lee SK, Seo JH et al. Predictive factors for local recurrence after endoscopic resection for early gastric cancer: long-term clinical outcome in a single-center experience. Surg Endosc 2010; 24: 2842-2849.
54. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75: 110-112.
55. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
56. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077.
57. Songun I, Putter H, Kranenbarg EM et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
58. Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010; 97: 643-649.
59. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
60. Bachmann MO, Alderson D, Edwards D et al. Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002; 89: 914-922.
61. Jensen LS, Nielsen H, Mortensen PB et al. Enforcing centralization for gastric cancer in Denmark. Eur J Surg Oncol 2010; 36 (suppl 1): S50-S54.
62. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
63. Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with paraaortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462.
64. Kodera Y, Ito S, Yamamura Y et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol 2003; 10: 898-902.
65. Bohner H, Zimmer T, Hopfenmuller W et al. Detection and prognosis of recurrent gastric cancer-is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology 2000; 47: 1489-1494.
66. Shiraishi N, Inomata M, Osawa N et al. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 2000; 89: 255-261.
67. Mikami K, Maekawa T, Shinohara T et al. Predictive factors of early recurrent death after a curative resection of gastric cancer. Int Surg 2009; 94: 144-148.
68. Mohri Y, Tanaka K, Ohi M et al. Prognostic significance of host- and tumorrelated factors in patients with gastric cancer. World J Surg 2010; 34: 285-290.
69. Saito H, Kuroda H, Matsunaga T et al. Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol 2010; 101: 622-625.
70. Lee SY, Hwang I, Park YS et al. Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes? Int J Oncol 2010; 36: 1461-1467.
71. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
72. Baiocchi GL, Tiberio GA, Minicozzi AM et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg 2010; 252: 70-73.
73. Kim J, Sun CL, Mailey B et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 2010; 21: 152-160.
74. Kim JW, Hwang I, Kim MJ, Jang SJ. Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci 2009; 24: 1158-1164.
75. Shiraishi N, Sato K, Yasuda K et al. Multivariate prognostic study on large gastric cancer. J Surg Oncol 2007; 96: 14-18.
76. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21: 3647-3650.
77. Oki E, Kakeji Y, Zhao Y et al. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol 2009; 16: 2510-2515.
78. Leite M, Corso G, Sousa S et al. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer 2011; 128: 1606-1613.
79. Lee HS, Choi SI, Lee HK et al. Distinct clinical features and outcomes of gastric cancers with microsatellite instability. Mod Pathol 2002; 15: 632-640.
80. Falchetti M, Saieva C, Lupi R et al. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008; 39: 925-932.
81. Tzanakis NE, Peros G, Karakitsos P et al. Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chir Belg 2009; 109: 606-611.
82. Yokobori T, Mimori K, Iwatsuki M et al. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 2009; 69: 3788-3794.
83. Al-Batran S, Pauligk C, Steinmetz K et al. Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first-line chemotherapy: results from the FLO versus FLP gastric cancer phase III trial of the AIO. J Clin Oncol 2008 suppl): 26 Abstract 4544.
84. Atmaca A, Pauligk K, Wirtz R et al. Validation of tumoral matrixmetalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer. J Clin Oncol 2010; 28 (15 suppl): Abstract 4017.
85. Pauligk C, Wirtz R, Steinmetz K et al. Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) mRNA expression in patients with metastatic gastric cancer receiving first-line chemotherapy. J Clin Oncol 2009; 27 (15 suppl): Abstract 4547.
86. Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
87. Okines AF, Norman AR, McCloud P et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20: 1529-1534.
88. Mauer AM, Kraut EH, Krauss SA et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005; 16: 1320-1325.
89. Louvet C, Andre T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-4548.
90. Al-Batran SE, Atmaca A, Hegewisch-Becker S et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-663.
91. Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
92. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-673.
93. Ajani JA, Faust J, Ikeda K et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 6957-6965.
94. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
95. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
96. Tebbutt NC, Cummins MM, Sourjina T et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 2010; 102: 475-481.
97. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
98. Martin M, Esteva FJ, Alba E et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009; 14: 1-11.
99. Saif MW, Makrilia N, Zalonis A et al. Gastric cancer in the elderly: an overview. Eur J Surg Oncol 2010; 36: 709-717.
100. Kang Y, Van Cutsem E, Rha Y et al. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010; 28 (18 suppl): Abstract LBA4007.
101. Thuss-Patience P, Deist T, Hinke A et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2009; 27 (15 suppl): Abstract 4540.
102. Catalano V, Graziano F, Santini D et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99: 1402-1407.
103. Ji SH, Lim do H, Yi SY et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009; 9: 110.
104. Stahl M, Muller C, Koster W, Wilke H. Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. Onkologie 2005; 28: 499-502.
105. Lorizzo K, Fazio N, Radice D et al. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother Pharmacol 2009; 64: 301-306.
106. Jo JC, Lee JL, Ryu MH et al. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 2007; 37: 936-941.
107. Hironaka S, Zenda S, Boku N et al. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.
108. Kodera Y, Ito S, Mochizuki Y et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007; 27: 2667-2671.
109. Hofheinz RD, Hartmann JT, Willer A et al. Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer 2004; 91: 834-838.